Literature DB >> 11920904

Maternal smoking: age distribution, levels of alpha-fetoprotein and human chorionic gonadotrophin, and effect on detection of Down syndrome pregnancies in second-trimester screening.

J A Crossley1, D A Aitken, S M L Waugh, T Kelly, J M Connor.   

Abstract

OBJECTIVES: To study the levels of maternal serum alpha-fetoprotein (AFP) and human chorionic gonadotrophin (hCG) in the second trimester in smokers and non-smokers with unaffected and Down syndrome pregnancies; to examine the rate of smoking in different maternal age groups in a population having routine prenatal screening; and to assess the effect of smoking on the detection rates for Down syndrome and corresponding false-positive rates, both overall and in different maternal age groups.
METHODS: Information on maternal smoking status, maternal age and serum marker levels was collected from case note searches and the screening programme database on 2272 unaffected singleton pregnancies, 36 unaffected twin pregnancies and 103 singleton Down syndrome pregnancies.
RESULTS: In unaffected pregnancies the smokers had a median age 3.3 years less than the non-smokers, while in the Down syndrome cases the corresponding age difference was 2.0 years. Median analyte levels in multiples of the median (MoM) in the unaffected singleton pregnancies were, for non-smokers: AFP=0.97, hCG=1.04; and for smokers, AFP=1.04, hCG=0.80. In the Down syndrome pregnancies the medians were, for non-smokers: AFP=0.69, hCG=2.49; and for smokers, AFP=0.70, hCG=1.53. Correction for smoking status gave median MoMs of 1.0 for both AFP and hCG in the unaffected pregnancies in both smokers and non-smokers. In the Down syndrome cases the corrected medians were, for non-smokers: AFP=0.67, hCG=2.29; and for smokers, AFP=0.73, hCG=1.99. Before correction for maternal smoking the overall detection rate for Down syndrome was 66.7% with a false-positive rate of 6.2%. After correction the detection rate was 67.7% with a false-positive rate of 4.9%. Between the smoking and non-smoking groups there was a significant difference in the detection rate (37.5% versus 76.0%) and the false-positive rate (1.8% versus 8.1%), which disappeared after correction for smoking status (detection rate 62.5% versus 69.3%, false-positive rate 3.9% versus 5.4%). No evidence of a lower incidence of Down syndrome in smokers was found.
CONCLUSIONS: While correcting AFP and hCG results for maternal smoking status will have little impact on the overall detection rate for Down syndrome, it may reduce the false-positive rate and will improve the accuracy of the risks given to individual women. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11920904     DOI: 10.1002/pd.313

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  9 in total

Review 1.  First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 2.  First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 3.  Second trimester serum tests for Down's Syndrome screening.

Authors:  S Kate Alldred; Jonathan J Deeks; Boliang Guo; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

4.  Maternal hormones during early pregnancy: a cross-sectional study.

Authors:  Tianhui Chen; Eva Lundin; Kjell Grankvist; Anne Zeleniuch-Jacquotte; Marianne Wulff; Yelena Afanasyeva; Helena Schock; Robert Johansson; Per Lenner; Goran Hallmans; Goran Wadell; Paolo Toniolo; Annekatrin Lukanova
Journal:  Cancer Causes Control       Date:  2010-01-19       Impact factor: 2.506

5.  Human chorionic gonadotropin and alpha-fetoprotein concentrations in pregnancy and maternal risk of breast cancer: a nested case-control study.

Authors:  Annekatrin Lukanova; Ritu Andersson; Marianne Wulff; Anne Zeleniuch-Jacquotte; Kjell Grankvist; Laure Dossus; Yelena Afanasyeva; Robert Johansson; Alan A Arslan; Per Lenner; Göran Wadell; Göran Hallmans; Paolo Toniolo; Eva Lundin
Journal:  Am J Epidemiol       Date:  2008-10-20       Impact factor: 4.897

6.  Maternal serum median levels of alpha-foetoprotein, human chorionic gonadotropin & unconjugated estriol in second trimester in pregnant women from north-west India.

Authors:  Gurjit Kaur; Jyoti Srivastav; Suresh Sharma; Anju Huria; Poonam Goel; Bir Singh Chavan
Journal:  Indian J Med Res       Date:  2013       Impact factor: 2.375

7.  Optimization of regional median equations of prenatal screening markers for trisomy 21 in a Chinese population.

Authors:  Liangpu Xu; Hailong Huang; Lin Zheng; Deqin He; Na Lin; Linshuo Wang; Yuan Lin
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

Review 8.  First trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-11-30

Review 9.  Urine tests for Down's syndrome screening.

Authors:  S Kate Alldred; Boliang Guo; Yemisi Takwoingi; Mary Pennant; Susanna Wisniewski; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.